Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00248183
Status:
COMPLETED
Last Update Posted:
2008-04-03
First Post:
2005-11-02
Brief Title:
A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder GAD
Sponsor:
Epix Pharmaceuticals Inc
Organization:
Epix Pharmaceuticals Inc
Study Overview
Official Title:
A Randomized Double Blind Placebo Controlled Multicenter Study To Evaluate The Efficacy Safety And Tolerability Of PRX-00023 In Patients With Generalized Anxiety Disorder GAD
Status:
COMPLETED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized double-blind placebo controlled multi-center outpatient study in adults with GAD
Patients 18-65 years of age with the diagnosis of GAD according to DSM-IV criteria who fulfill the inclusionexclusion criteria will be enrolled in this study
Patients 18-65 years of age with the diagnosis of GAD according to DSM-IV criteria who fulfill the inclusionexclusion criteria will be enrolled in this study
Detailed Description:
This is a randomized double-blind placebo controlled multi-center outpatient study in adults with GAD
Patients 18-65 years of age with the diagnosis of GAD according to DSM-IV criteria who fulfill the inclusionexclusion criteria will be enrolled in this study
This is a randomized double-blind placebo controlled multi-center outpatient study in adults with GAD
Patients 18-65 years of age with the diagnosis of GAD according to DSM-IV criteria who fulfill the inclusionexclusion criteria will be enrolled in this study
Patients 18-65 years of age with the diagnosis of GAD according to DSM-IV criteria who fulfill the inclusionexclusion criteria will be enrolled in this study
This is a randomized double-blind placebo controlled multi-center outpatient study in adults with GAD
Patients 18-65 years of age with the diagnosis of GAD according to DSM-IV criteria who fulfill the inclusionexclusion criteria will be enrolled in this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None